GLP-1 peptide therapy, such as Ozepmpic, Mounjaro, and Trulicty, may have insurance coverage options, depending on your insurance coverage
As the availability of compounded semaglutide changes, we are actively working to expand treatment options for patients in an affordable, sustainable way
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges
Tirzepatide often produces greater average weight loss due to its dual-receptor action
Offered as a daily tablet, Oral Wegovy suits those seeking a weight loss medication without injections